The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine ...

As of December 2, 2024, the average one-year price target for BioNTech SE - Depositary Receipt is $139.40/share. The forecasts range from a low of $100.23 to a high of $180.02.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer has also agreed to reimburse BioNTech for part of these royalties. More about BioNTech SE BioNTech SE is a biotechnology company primarily focused on developing and manufacturing ...

BioNTech SE (NASDAQ:BNTX), the German biotechnology company that rose to prominence with its COVID-19 vaccine, is navigating a crucial transition period as it seeks to leverage its mRNA technology ...